Table 4 Association of tumor ARTN, GFRα1, GFRα3 and SDC3 protein expression with five year relapse-free survival (RFS) and overall survival (OS) in patients with ER-positive/ER-negative or HER2-positive/HER2-negative mammary carcinoma
RFS (%) | P | OS (%) | P | |
|---|---|---|---|---|
ER-positive | ||||
ARTN-GFRα1-/ARTN + GFRα1+ | 81.0/50.0 | 0.153 | 90.5/50.0 | 0.044 |
ARTN-GFRα3-/ARTN + GFRα3+ | 81.8/50.0 | 0.199 | 86.4/50.0 | 0.138 |
ARTN- SDC3-/ARTN + SDC3+ | 54.2/66.7 | 0.679 | 66.7/66.7 | 0.903 |
ER-negative | ||||
ARTN-GFRα1-/ARTN + GFRα1+ | 76.0/16.7 | 0.002 | 84.0/16.7 | 0.001 |
ARTN-GFRα3-/ARTN + GFRα3+ | 75.0/25.0 | 0.009 | 81.3/25.0 | 0.005 |
ARTN- SDC3-/ARTN + SDC3+ | 71.4/50.0 | 0.532 | 71.4/50.0 | 0.532 |
HER2-positive | ||||
ARTN-GFRα1-/ARTN + GFRα1+ | 75.0/100.0 | 0.605 | 87.5/100.0 | 0.724 |
ARTN-GFRα3-/ARTN + GFRα3+ | NA | NA | ||
ARTN- SDC3-/ARTN + SDC3+ | NA | NA | ||
HER2-negative | ||||
ARTN-GFRα1-/ARTN + GFRα1+ | 78.9/22.2 | 0.001 | 86.8/22.2 | 0.001 |
ARTN-GFRα3-/ARTN + GFRα3+ | 79.1/37.5 | 0.01 | 83.7/37.5 | 0.005 |
ARTN- SDC3-/ARTN + SDC3+ | 64.3/60.0 | 0.855 | 71.4/60.0 | 0.679 |